State Street SPDR S&P Pharmaceuticals ETF (NY:XPH)

62.37 -0.54 (-0.87%)

Delayed Quote Updated: 11:38 AM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Pharmaceuticals ETF

< Previous 1 2 3 Next >

Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work ↗

May 20, 2025

The Trump administration unveiled the first details Tuesday on how it plans to lower drug prices "drastically" in the U.S.

Via Investor's Business Daily

Topics ETFs Government

Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion ↗

May 19, 2025

Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.

Via Benzinga

Topics Government

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks ↗

May 08, 2025

Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.

Via Benzinga

Topics ETFs Government

Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report ↗

April 28, 2025

Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and...

Via Stocktwits

Topics Government Intellectual Property Lawsuit

ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot ↗

April 18, 2025

Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.

Via Benzinga

Topics ETFs

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Via Benzinga

Topics Government World Trade

Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On? ↗

April 03, 2025

Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential tariffs. Other key questions remain.

Via Benzinga

Topics World Trade

Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In ↗

March 06, 2025

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.

Via Stocktwits

Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4 ↗

March 04, 2025

CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key...

Via Stocktwits

Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027 ↗

February 28, 2025

Perrigo Company shares surged after issuing financial targets for 2025 & 2025-2027 on investor day. Expect sales growth, EPS, and margin expansion. 'Three-S' plan will enhance cash flow & shareholder...

Via Benzinga

Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors ↗

February 17, 2025

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.

Via Benzinga

Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish ↗

January 28, 2025

The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.

Via Stocktwits

AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance

July 26, 2024

AstraZeneca beat earnings-per-share (EPS) estimates and raised guidance, but shares still fell. Investors should watch for developments around the drug Enhertu.

Via MarketBeat

Topics ETFs

Purdue Pharma Bankruptcy Plan Rejected by Supreme Court, Billionaire Sacklers to Face Lawsuits ↗

June 27, 2024

The Supreme Court has rejected Purdue Pharma's bankruptcy plan, exposing the Sackler family to lawsuits over their role in the opioid crisis. This decision impacts victims, state and local governments,...

Via Benzinga

Topics Bankruptcy Lawsuit

A Look At Pharma ETFs Post Q1 Earnings ↗

May 07, 2024

Pharma ETFs have delivered mixed performances over the past month.

Via Talk Markets

Topics ETFs

Organon Beats On Q1, Women's Health Leads the Charge ↗

May 02, 2024

Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared.

Via Benzinga

A Look At Pharma ETFs After Q4 Earnings ↗

February 12, 2024

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.

Via Talk Markets

Topics ETFs

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

September 01, 2023

Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.

Via MarketBeat

Topics Economy

Pharma ETFs in Focus Post Q2 Earnings ↗

August 11, 2023

Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth.

Via Talk Markets

Topics ETFs

Pharma ETFs Gain Post Q1 Earnings ↗

May 09, 2023

Pharma ETFs have been in the green over the past month.

Via Talk Markets

A Look At Pharma ETFs Post Q4 Earnings ↗

February 08, 2023

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month.

Via Talk Markets

Pharma ETFs In Focus Post Q3 Earnings ↗

November 09, 2022

Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month.

Via Talk Markets

Large Cap Biopharma- Well Positioned For Choppy Markets ↗

February 14, 2022

If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets.

Via Talk Markets

3 Pharma Stocks Yielding Over 3% ↗

January 18, 2022

The Pharma industry faced headwinds in 2021 as hospitals delayed procedures and elective surgeries.

Via Talk Markets

7 Pharmaceutical Stocks That Could Make You Rich ↗

January 06, 2022

Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich

Via InvestorPlace

The Bear Market Is Already Here – But Not For Dividend Investors ↗

December 22, 2021

While the broad stock market indices remain at near-record levels, there are sectors of the market that have dropped into correction or even bear market territory over recent months.

Via Talk Markets

Wave of Solid Q3 Earnings Push Pharma ETFs Higher ↗

November 09, 2021

The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.

Via Talk Markets

The Cost Of Saving The Economy: $1.7 Billion Per Hour Every Hour ↗

August 20, 2021

the Fed has bought $4 trillion bonds in the past 18 months, twice the amount the US spent on War in Afghanistan past 20 years as it, and other global central banks, have spent $834 million every hour...

Via Talk Markets

Topics Bonds Economy

The 2 Best Pharma Stocks to Buy on Dips ↗

June 23, 2021

Because the COVID-19 pandemic is under control in most major economies, the hype surrounding vaccine producers is gradually tapering off.

Via Talk Markets

3 Top Pharma Stocks to Buy This Month ↗

June 09, 2021

In 2020, pharmaceutical stocks came to the forefront as healthcare companies were searching for treatments for COVID-19.

Via Talk Markets

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.